Spur Therapeutics Prepares for ESGCT Annual Congress Presentation
Recently, Spur Therapeutics announced plans to present groundbreaking clinical data regarding its gene therapy candidate, avigbagene parvec (FLT201), targeting Gaucher disease. This significant presentation is scheduled to occur during the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress, which will be held from October 7-10.
Essential Details of the Presentation
The presentation titled, "Long-term durability of FLT201: an investigational gene therapy for Gaucher disease Type 1 encoding an engineered variant of the GCase enzyme," will be pivotal in showcasing the advancements of this innovative therapy. Scheduled for October 8, 2025, from 14:00 to 15:30 CEST (8:00 to 9:30 a.m. EST), the session will be presided over by Dr. Pilar Giraldo from Hospital Universitario Quironsalud.
Link to Abstracts
Abstracts related to this presentation are now accessible on the official ESGCT website, making essential insights available to the public and industry stakeholders alike.
About Spur Therapeutics
As a clinical-stage biotechnology company, Spur Therapeutics is dedicated to the development of pioneering gene therapies aimed at alleviating chronic debilitating conditions. The company believes in optimizing every component of its product candidates to unleash the full potential of gene therapy, thereby achieving remarkable clinical outcomes.
Clinical Impacts and Aspirations
Notably, Spur is in the process of advancing not only its lead candidate for Gaucher disease but also a preclinical gene therapy targeting Parkinson's disease. This dual focus illustrates Spur's commitment to expanding its impact in the realm of genetic medicine and pursuing life-changing therapies that lead to brighter futures for patients.
Connecting with Spur Therapeutics
For further inquiries or information, individuals can reach out to Naomi Aoki via email at naomi.aoki@spurtherapeutics.com or call +1 617 283 4298. Spur also maintains an engaging online presence; interested parties are invited to visit their website at www.spurtherapeutics.com or connect via LinkedIn.
Frequently Asked Questions
What is the primary focus of Spur Therapeutics?
Spur Therapeutics primarily focuses on developing gene therapies for chronic conditions, notably Gaucher disease and Parkinson's disease.
When will Spur present at the ESGCT Congress?
Spur Therapeutics is set to present on October 8, 2025, at the ESGCT Annual Congress.
Who is presenting the data on FLT201?
The presentation will be delivered by Dr. Pilar Giraldo from Hospital Universitario Quironsalud.
How can I access the abstracts from the presentation?
The abstracts are available on the ESGCT website for public access.
Where can I find more information about Spur Therapeutics?
More information can be found on their official website at www.spurtherapeutics.com.